Bayer AG, Research & Early Development, Disease Understanding and Precision Biomarkers, Division Pharmaceuticals, Wuppertal, Germany.
Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany.
J Hum Hypertens. 2023 May;37(5):345-353. doi: 10.1038/s41371-022-00701-0. Epub 2022 May 9.
Treatment resistant hypertension (TRH) appears of particular relevance in patients with chronic kidney disease (CKD). However, causes and consequences of TRH in CKD patients remain incompletely understood. Therefore, we analyzed the prevalence of apparent TRH (aTRH), and phenotypic characteristics and prognosis associated with aTRH among participants of the German Chronic Kidney Disease (GCKD) study. As insufficient medication adherence has been shown to be a frequent cause of pseudoresistance, we also assessed treatment adherence. Study participants were classified as having aTRH, controlled hypertension and uncontrolled hypertension based on study visit blood pressure and self-reported medication intake. Drug adherence was assessed by comparing self-reported antihypertensive medication with detectable urinary drug metabolites measured by mass spectroscopy. Out of 4901 individuals included in this study, 38% were classified as having aTRH. Male sex, older age, lower estimated glomerular filtration rate (eGFR), higher body mass index (BMI), higher urine albumin-to-creatinine ratio (UACR) and presence of diabetes mellitus were independently associated with higher prevalence of aTRH in a multivariable adjusted regression model. Patients classified as aTRH had higher risk for major adverse cardiovascular events and worsening of kidney disease compared to patients with no aTRH after multivariate adjustment for potential confounders. There was a high agreement between self-reported medication and detectable urinary drug metabolites. In conclusion, in a cohort of Caucasian patients with moderately severe CKD, aTRH was highly prevalent and, in most cases, likely not caused by low medication adherence. Furthermore, aTRH was linked to cardio-renal endpoints, emphasizing the need for improved management.
治疗抵抗性高血压(TRH)在慢性肾脏病(CKD)患者中显得尤为重要。然而,CKD 患者中 TRH 的原因和后果仍不完全清楚。因此,我们分析了德国慢性肾脏病(GCKD)研究参与者中明显 TRH(aTRH)的患病率,以及与 aTRH 相关的表型特征和预后。由于药物依从性不足被认为是假性抵抗的常见原因,我们还评估了治疗依从性。研究参与者根据研究就诊时的血压和自我报告的药物摄入量被分类为 aTRH、血压控制良好和血压控制不佳。药物依从性通过比较自我报告的抗高血压药物与通过质谱法检测到的可检测尿液药物代谢物来评估。在这项研究中,共有 4901 人被纳入,其中 38%被分类为 aTRH。多变量调整回归模型显示,男性、年龄较大、估算肾小球滤过率(eGFR)较低、体重指数(BMI)较高、尿白蛋白与肌酐比值(UACR)较高以及患有糖尿病与 aTRH 患病率较高独立相关。与无 aTRH 的患者相比,经过多变量调整混杂因素后,被分类为 aTRH 的患者发生主要不良心血管事件和肾脏疾病恶化的风险更高。自我报告的药物与可检测尿液药物代谢物之间具有高度一致性。总之,在一组高加索裔中重度 CKD 患者中,aTRH 患病率很高,在大多数情况下,不太可能是由于药物依从性低引起的。此外,aTRH 与心脏肾脏终点相关,强调需要改善管理。